What are you talking about? IMU has been funding 5 IP since 5 years ago with 1 Ph2 clinical trial completed, 1 about to start Ph2 clinical trial, 1 about to complete Ph1b clinical trial and 2 other well advanced in Ph1 clinical trials and they've just completed a CR recently at a premium despite having $45M in cash at the start of this year and a total of around $45M in R&D rebate outstanding. How is that even remotely the same as CHM's development and the struggle to fund their programs????
If you really had fund then you would be buying IMU shares given how cheap they are right now given the fundamental, even 8c would still be considered cheap.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)